Drug Trial Radar · NCT04305054
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
335
Actual
Start
Jul 1, 2020
Primary completion
May 18, 2026
Study completion May 18, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn: * About the safety and how well people tolerate pembrolizumab given with other treatments * How many people have melanoma that responds (gets smaller or goes away) to treatment
Conditions
- Melanoma
Interventions
PembrolizumabBiological
Administered via IV infusion at a specified dose on specified days
VibostolimabBiological
Administered via IV infusion at a specified dose on specified days
Pembrolizumab/QuavonlimabBiological
Administered via IV infusion at a specified dose on specified days
LenvatinibDrug
Administered via oral capsule at a specified dose on specified days
Favezelimab/PembrolizumabBiological
Administered via IV infusion at a specified dose on specified days
ATRADrug
Administered via oral capsule at a specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-in phaseTime frame: Up to ~3 weeks
- Percentage of participants who experience an adverse event (AE): Safety lead-inTime frame: Up to ~3 weeks
- Percentage of participants who discontinue study treatment due to an AE: Safety lead-inTime frame: Up to ~3 weeks
- Percentage of participants who experience an adverse event (AE)Time frame: Up to ~28 months
- Percentage of participants who discontinue study treatment due to an AETime frame: Up to ~24 months
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)Time frame: Up to ~30 months
Locations
60 sites in 14 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute ( Site 2009)
Los Angeles, California
UCLA Hematology & Oncology ( Site 2004)
Los Angeles, California
Providence Saint John's Health Center ( Site 2010)
Santa Monica, California
University of Colorado, Anschutz Cancer Pavilion ( Site 2012)
Aurora, Colorado
University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 2026)
Gainesville, Florida
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022)
Baltimore, Maryland
R.J. Zuckerberg Cancer Center ( Site 2032)
Lake Success, New York
NYU Clinical Cancer Center ( Site 2002)
New York, New York
Duke Cancer Institute ( Site 2005)
Durham, North Carolina
Martha Morehouse Tower ( Site 2020)
Columbus, Ohio
Oregon Health & Science University ( Site 2013)
Portland, Oregon
University of Pennsylvania Abramson Cancer Center ( Site 2008)
Philadelphia, Pennsylvania
West Cancer Center - East Campus ( Site 2014)
Germantown, Tennessee
Mays Cancer Center ( Site 2025)
San Antonio, Texas
Inova Schar Cancer Institute ( Site 2011)
Fairfax, Virginia
Sanatorio Finochietto ( Site 2245)
Buenos Aires, Argentina
Clinica Adventista Belgrano-Oncology ( Site 2242)
Caba., Buenos Aires, Argentina
Instituto Alexander Fleming-Alexander Fleming ( Site 2243)
Buenos Aires, Buenos Aires F.D., Argentina
Calvary Mater Newcastle-Medical Oncology ( Site 2404)
Waratah, New South Wales, Australia
Melanoma Institute Australia ( Site 2402)
Wollstonecraft, New South Wales, Australia
Tasman Oncology Research Pty Ltd ( Site 2403)
Southport, Queensland, Australia
Fiona Stanley Hospital ( Site 2401)
Murdoch, Western Australia, Australia
CIDO SpA-Oncology ( Site 2256)
Temuco, Araucania, Chile
IC La Serena Research ( Site 2254)
La Serena, Coquimbo Region, Chile
FALP-UIDO ( Site 2251)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 2257)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 2252)
Santiago, Region M. de Santiago, Chile
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2261)
Bogotá, Bogota D.C., Colombia
Fundación Valle del Lili ( Site 2265)
Cali, Valle del Cauca Department, Colombia
A.P.H. Paris, Hopital Saint Louis ( Site 2107)
Paris, France
Hopital La Timone ( Site 2103)
Marseille, Bouches-du-Rhone, France
CHU de Bordeaux- Hopital Saint Andre ( Site 2108)
Bordeaux, Gironde, France
Institut Claudius Regaud ( Site 2105)
Toulouse, Haute-Garonne, France
Gustave Roussy ( Site 2101)
Villejuif, Île-de-France Region, France
C.H. Lyon Sud ( Site 2102)
Pierre-Bénite, Rhone, France
European Interbalkan Medical Center-Oncology Department ( Site 2211)
Thessaloniki, Greece
General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 2212)
Athens, Attica, Greece
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 2221)
Szeged, Csongrád megye, Hungary
HaEmek Medical Center ( Site 2703)
Afula, Israel
Rambam Health Care Campus-Oncology ( Site 2704)
Haifa, Israel
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.